One in four people experience mild side effects from Covishi

One in four people experience mild side effects from Covishield COVID-19 vaccine: Lancet study


PTI | New Delhi | Updated: 28-04-2021 15:12 IST | Created: 28-04-2021 15:12 IST
One in four people experience mild, short lived systemic side effects after receiving either the COVID-19 preventive by Pfizer or AstraZeneca vaccine -- known as Covishield in India -- with headache, fatigue and tenderness the most common symptoms, according to a study published in the Lancet Infectious Diseases journal.
The researchers from King's CollegeLondon in the UK also found that most systemic side effects -- meaning side effects excluding where the injection took place -- peaked within the first 24 hours following vaccination and usually lasted 1-2 days.
The analysis of data from the ZOE COVID Symptom Study app found much fewer side effects in the general population with both the Pfizer and AstraZeneca vaccines than reported in trials.

Related Keywords

United Kingdom , India , London , City Of , King College London , Tim Spector , Pfizer , Astrazeneca , Professor At King College London , Lancet Infectious Diseases , Professor Tim Spector , Arthralgia , Zoe Covid Symptom Study , Warmth , Zoe Covid Symptom Study App , Covishield , King 39s College , Lancet Infectious , King 39s College London , ஒன்றுபட்டது கிஂக்டம் , இந்தியா , லண்டன் , நகரம் ஆஃப் , கிங் கல்லூரி லண்டன் , நேரம் ஸ்பெக்டர் , ஃபைசர் , ப்ரொஃபெஸர் இல் கிங் கல்லூரி லண்டன் , ப்ரொஃபெஸர் நேரம் ஸ்பெக்டர் , ந்திய ,

© 2025 Vimarsana